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ABSTRACT
DNA polymerase theta (POLQ)-mediated end join-
ing (TMEJ) is a distinct pathway for mediating DNA
double-strand break (DSB) repair. TMEJ is required
for the viability of BRCA-mutated cancer cells. It is
crucial to identify tumors that rely on POLQ activity
for DSB repair, because such tumors are defective
in other DSB repair pathways and have predicted
sensitivity to POLQ inhibition and to cancer thera-
pies that produce DSBs. We define here the POLQ-
associated mutation signatures in human cancers,
characterized by short insertions and deletions in
a specific range of microhomologies. By analyzing
82 COSMIC (Catalogue of Somatic Mutations in Can-
cer) signatures, we found that BRCA-mutated can-
cers with a higher level of POLQ expression have a
greatly enhanced representation of the small inser-
tion and deletion signature 6, as well as single base
substitution signature 3. Using human cancer cells
with disruptions of POLQ, we further show that TMEJ
dominates end joining of two separated DSBs (distal
EJ). Templated insertions with microhomology are
enriched in POLQ-dependent distal EJ. The use of
this signature analysis will aid in identifying tumors
relying on POLQ activity.
INTRODUCTION
DNA double-strand breaks (DSBs) are deleterious lesions
that can lead to cell death if not repaired. Additionally,
DSB repair processes have the potential to introduce mu-
tations and chromosome rearrangements. There are three
major pathways for repair of DSBs: (i) nonhomologous
end joining (NHEJ), (ii) homologous recombination (HR)
and (iii) DNA polymerase theta ()-mediated end joining
(TMEJ; Figure 1). NHEJ is often the predominant path-
way for the repair of DSBs that occur outside of replication
(1,2). In the absence of NHEJ, the broken ends are resected
by nucleases and then the exposed single-stranded DNA (ss-
DNA) tails are processed by HR or TMEJ. HR uses an un-
damaged homologous DNA template to repair DNA ini-
tiated from ssDNA tails, as does the related single-strand
annealing (SSA) process (1,3). TMEJ mediates the joining
of two resected 3′ ends harboring DNA sequence microho-
mology (MH) in a Ku-independent manner (4). NHEJ and
TMEJ can occur throughout the cell cycle but HR operates
only in S and G2 stages when a sister chromatid is present
(5,6). The choice of DSB repair pathway influences the fi-
delity of DSB repair, which eventually influences the rate
of tumorigenesis. TMEJ is an important alternative to the
major DSB repair pathways, HR and NHEJ. The require-
ment of POLQ for the viability of BRCA-mutated cancer
cells underscores the importance of TMEJ (7). Accordingly,
tumors with disrupted HR or NHEJ pathways, including
BRCA1/2, rely on POLQ activity for DSB repair, and are
sensitive to POLQ inhibition, PARP inhibition or cancer
therapies introducing DSBs (7–9). To guide personalized
therapies, there is an urgent need to have a general method
to identify tumors that rely on POLQ activity.
POLQ is a unique multifunctional enzyme. It has an
N-terminal helicase-like domain (HLD) linked to a C-
terminal A-family DNA polymerase domain via a cen-
tral region (10). The POLQ-HLD and polymerase domains
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Figure 1. POLQ is an important alternative for NHEJ or HR. Upon DSB formation, NHEJ factors inhibit DNA resection and stimulate end joining.
When DSB damage is unable to be repaired by NHEJ, 3′ DNA tails are generated from DNA end resection by nucleases. The 3′ DNA tails are processed
by TMEJ or BRCA-mediated HR. POLQ becomes more important when NHEJ or HR is not available and repairs DSBs at the expense of introducing
mutation signatures. Detection of those signatures in tumor biopsy may be a useful approach to influence treatment decision.
both contribute to end joining (11–13). Although the ma-
jority of A-family DNA polymerases including Escherichia
coli pol I and DNA polymerase  are high-fidelity poly-
merases, POLQ is error-prone (14,15). POLQ harbors an
exonuclease-like domain but it lacks a 3′→5′ proofread-
ing activity (10). Because of its low fidelity and the unique
thumb domain that carries positively charged residues to
grasp the unstable primer terminus, POLQ can extend DNA
from mismatched primers (16).
DNA repair, including TMEJ, is important to avoid cell
death from DNA damage. DNA repair processes are not
always perfect, however, and can contribute to base sub-
stitutions, deletions and insertions in cancer genomes. Se-
quencing technologies have helped to decipher patterns of
somatic mutations in cancer genomes (17,18). Originally, 30
independent COSMIC (Catalogue of Somatic Mutations in
Cancer) signatures were identified (17). These were recently
updated, and new COSMIC mutation signatures including
single base substitution (SBS) and small insertion and dele-
tion (ID) signatures are being used to characterize cancer
genomes (18). SBS signatures are used to classify single-
nucleotide mutations according to 96 types: 6 types of sub-
stitution (C>A, C>G, C>T, T>A, T>C, T>G) multiplied
by 4 possible 5′ flanking bases (A, C, G or T) and 4 possible
3′ flanking bases (A, C, G or T). ID signatures are used to
classify insertion and deletion mutations into 83 ID types:
12 types of 1 bp deletions, 12 types of 1 bp insertions, 24
types of ≥2 bp deletions, 24 types of ≥2 bp insertions and
11 types of ≥2 bp deletions at MHs (18). The mechanism of
origin of some of these signatures is understood, but most
arise by unknown mechanisms.
In TMEJ, POLQ joins broken ends utilizing MH exposed
after DNA resection. This activity introduces short DNA
deletions, while protecting against large catastrophic dele-
tions (11,19). This unique activity of POLQ yields a dis-
tinctive mutation pattern that has been proposed to be re-
lated to COSMIC3, a mutational signature often found in
BRCA-mutated cancers (20,21). This mutation signature is
associated with up to 50 bp deletions with overlapping MHs
at end-joining sites (17,18). POLQ mRNA overexpression
has been reported in human malignancies (22,23). However,
a clear demonstration that POLQ status influences the oc-
currence of the COSMIC3 signature in tumors is currently
lacking.
Here, we describe experiments to analyze which COS-
MIC signatures (18) are enriched among 82 signatures in
BRCA-mutated cancers that express high levels of wild-type
POLQ. We identified three such signatures: single base sub-
stitution signature 3 (SBS3), a recently updated version re-
lated to COSMIC3, and small insertion and deletion sig-
natures 6 and 8 (ID6 and ID8). The detection of those sig-
natures in whole genome data from individual tumors may
be useful to monitor POLQ activity for cancer treatment.
However, SBS3, ID6 and ID8 are not designed to moni-
tor POLQ activity, so they do not comprehensively reflect
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the pipeline to define POLQ-dependent mutation signatures
by more intensive analysis of the mechanism of POLQ mu-
tagenesis.
As part of a direct exploration of the mechanism of
POLQ action and mutagenesis, we identify here a situation
in which POLQ is used in cells. Templated insertion is one of
the hallmarks of POLQ-associated mutation (24). It is evo-
lutionally conserved in Drosophila (25), Caenorhabditis ele-
gans (26), mouse (27) and human (11). We show that POLQ
generates templated insertions during nuclease-induced dis-
tal end joining (distal EJ), a process that promotes liga-
tion between two separated DSBs. A physiological exam-
ple of distal EJ is class switch recombination (CSR), in-
volving two DSBs in antibody genes. During CSR in mouse
B cells, POLQ introduces templated insertions of between
2 and 35 bp (27). Homologous sequences for those inser-
tions arose from sequences directly adjacent to the resected
ends or from sequences many kb distant (27). In this study,
we find that insertions initiated and ended with MH are
enriched in POLQ-dependent distal EJ. Distal EJ occurs
when the two originally separated DSBs are not properly
repaired at each DSB site by NHEJ (proximal EJ) or HR.
We conclude that TMEJ is a major pathway to mediate
distal EJ.
MATERIALS AND METHODS
Analysis of cancer mutational signatures
We used somatic single-nucleotide variant,
insertion/deletion and gene expression information to
distinguish samples with mutant and wild-type POLQ,
BRCA1 and BRCA2. Among the variant classifications,
frameshift deletion, frameshift insertion and nonsense
mutation were selected and used as somatic muta-
tions. In the sample, if a single-nucleotide variant or an
insert/deletion in a specific gene was a somatic mutation,
it was called a mutant. If there was no mutation in the
gene or if the mutation was not a somatic mutation, it
was called a wild type. A gene expression level below
the 33rd percentile was considered low and above the
33rd percentile was considered high. Somatic mutation
and insertion/deletion data were obtained from the Pan-
Cancer Analysis of Whole Genomes (PCAWG) consensus
callsets downloaded from the ICGC Data Portal (https:
//dcc.icgc.org/releases/PCAWG/consensus snv indel).
Gene expression data were from PCAWG transcriptome
analysis results downloaded from the ICGC Data Por-
tal (https://dcc.icgc.org/releases/PCAWG/transcriptome/
gene expression). Version 2 and 3 COSMIC muta-
tional signatures were downloaded from COSMIC
(https://cancer.sanger.ac.uk/cosmic/signatures). We
matched the sample ID of the mutational signature
data with the PCAWG consensus callset and transcriptome
analysis results’ data to validate the change in signature
proportion under the POLQ, BRCA1 and BRCA2 mu-
tation or expression conditions of cancer samples. We
used the Wilcoxon signed-rank test to determine which
signatures are associated with POLQ status. We further
adjusted P-value by the Bonferroni method for stringent
statistical significance.
CRISPR/Cas9-mediated gene disruption
We used the GeneArt CRISPR Nuclease Vector with OFP
Reporter Kit from Thermo Fisher. Two oligonucleotides
(5′-GATTCGTTCTCGGGAAGCGGGTTTT and 5′-CC
GCTTCCCGAGAACGAATCCGGTG) that code for
target-specific crRNA were annealed and ligated into the
linearized GeneArt CRISPR Nuclease Vector to target
exon 1 of POLQ (28). The GeneArt CRISPR Nuclease Vec-
tor encoding a custom single-guide RNA containing the
POLQ targeting sequence (crRNA) and a Cas9 nuclease-
recruiting sequence (tracrRNA), Cas9 nuclease and orange
fluorescent protein (OFP) as a co-expression marker was
transfected to DR-U2OS (29) or EDS-7F2 (30) cells with
Lipofectamine LTX (Invitrogen). After the transfection,
OFP-positive single cell clones were sorted into 96-well
plates by flow cytometry. Genomic DNA isolated from indi-
vidual clones was amplified by PCR with POLQ ex1 F (5′-
GGGAGGTTTGAGTTTGAAGAC) and R (5′-GTCAC
AGAGAAGGGGAGTAG) primers. The targeted genomic
DNA sequence of the complete POLQ knockout cell lines
was confirmed by direct sequencing of PCR products am-
plified with POLQ ex1 F and R primers, and sequencing af-
ter TA cloning of the PCR products. The absence of POLQ
in complete POLQ knockout cell lines was also confirmed
by immunoblotting with the POLQ-specific 1B1 antibody
(28,31).
shRNA vectors
We used shRNA vectors obtained from the MD An-
derson core facility: sh53BP1 (V3LHS 635694) (32), sh-
PRKDC (DNA-PKcs) (V2LHS 94774) (28) and shControl
(RHS4346).
Antibodies
We used the following antibodies: 1B1, monoclonal anti-
POLQ 1:10 000 (31); A300-516A, polyclonal anti-DNA-
PKcs 1:5000; A300-272A, polyclonal anti-53BP1 1:10 000;
F7425, monoclonal anti--Tubulin 1:8000; sc73614, mon-
oclonal anti-vinculin 1:1000; T5168, HRP (horseradish
peroxidase)-conjugated anti-mouse IgG 1:10 000; and
A0168, HRP-conjugated anti-rabbit IgG 1:10 000.
DR-GFP assays
We followed a previously published method (33). A total of
0.8 g of the I-SceI expression vector pCBASce was trans-
fected to 2 × 105 DR-U2OS cells with Lipofectamine 2000.
To determine the amount of HR, the percentage of GFP-
positive cells was quantitated by flow cytometric analysis 3
days after transfection using a BD FACSDiva.
Measuring the frequency of imprecise NHEJ of an I-SceI-
generated DSB
PCR amplification for direct-repeat GFP (DR-GFP) I-SceI
region was performed using pooled genomic DNA from
pCBASce-transfected cells, KOD Xtreme Hot Start DNA
Polymerase (Toyobo) and the following primers: [DRGFP
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5′-AAGTCGTGCTGCTTCATGTG-3′. The PCR prod-
ucts were incubated with I-SceI, BcgI or I-SceI + BcgI (dou-
ble digestion). Cells that repair an I-SceI-generated DSB by
imprecise NHEJ, SSA or HR lose the I-SceI site. In addi-
tion, cells that repair the DSB by SSA or HR replace the
I-SceI site with a BcgI site, allowing for the discrimination
of specific repair pathways (33).
Generation of I-SceI-induced DSBs in EDS-7F2
Packaging of the pQCXIH-I-SceI retroviral vectors and in-
fection of cell cultures were performed as previously de-
scribed (30). The selection for cells infected with pQCXIH-
I-SceI was achieved by growth in medium containing
50 g/ml hygromycin (Sigma) for 14 days with medium
changes every 2 days to allow for expression of I-SceI en-
donuclease and the generation of DSBs. The analysis of
the frequency of GFP-positive (GFP+) and DsRed positive
(DsRed+) cells was performed by fluorescence-activated
cell sorting (FACS) using a BD FACSAria Fusion in-
strument (BD Biosciences). The cells were trypsinized, an
equal volume of growth medium was added and they were
counted and pelleted. To prevent aggregation, the cells
were then resuspended in 10 ml of ice-cold Dulbecco’s
phosphate-buffered saline (PBS; w/o Ca or Mg) containing
100 g/ml Proteinase K (Sigma) by vigorous pipetting. The
cells were incubated for 10 min on ice, pipetting twice more
during the incubation. This treatment with Proteinase K is
necessary to prevent cell aggregation. Following the incuba-
tion, 2 ml of Dulbecco’s PBS (w/o Ca or Mg) containing 1%
bovine serum albumin (Sigma) was added to block further
digestion with Proteinase K. The cells were then pelleted
and resuspended in Dulbecco’s PBS (w/o Ca or Mg) at ∼1
× 106 cells/ml for analysis by flow cytometry as reported
(30).
Sample preparation for proximal end joining
We used the GeneArt CRISPR Nuclease Vector with OFP
Reporter Kit from Thermo Fisher. Two oligos (5′-CTTGC
GACCTTGACCATCTTGTTTT and 5′-AAGATGGTC
AAGGTCGCAAGCGGTG) were annealed and ligated to
the linearized GeneArt CRISPR Nuclease Vector to target
exon 6 of HPRT. The GeneArt CRISPR Nuclease Vector
was then transfected to DR-U2OS cells with Lipofectamine
LTX (Invitrogen). Forty-eight hours after the transfection,
OFP (co-expression marker)-positive cells were isolated by
flow cytometry. Genomic DNA was isolated from OFP-
positive cells from three independent experiments and was
amplified by PCR using primers (HPRTF: 5′-TCTTACT
GCTTGCTGAGGGC and HPRTR: 5′-TAATTTTGCAA
GGGGGCCCA) and KOD Xtreme Hot Start DNA Poly-
merase (Toyobo) (95◦C for 2 min, followed by 35 cycles of
95◦C for 30 s, 63◦C for 30 s and 68◦C for 45 s, last strand
elongation at 68◦C for 5 min). A total of 20.4 ng of genomic
DNA corresponding to 3000 cells (6000 HPRT loci) was
used for each PCR reaction, unless otherwise indicated. The
formula (6.81 × 10−12 g/cell) determined the cell number
from genomic DNA amount. The PCR products (546 bp
for wild-type HRPT locus) were separated by 1% agarose
gel and the products (100–650 bp) were cut out from the gel
and purified with QIAquick gel purification kit (Qiagen).
Sample preparation for joining at distal joined junctions in
EDS-7F2 cells
After I-SceI expression, genomic DNA was isolated from
GFP-positive EDS-7F2 cells. PCR amplification of the
junction region was performed using pooled genomic
DNA from GFP-positive EDS-7F2 cells (54 ng of ge-
nomic DNA, corresponding to 7930 cells), KOD Xtreme
Hot Start DNA Polymerase (Toyobo) and the following
primers: [7F2GFP NGS F] 5′-GTCCCAAATCTGGCGG
AG-3′ and [7F2GFP NGS R] 5′-GTAGCGGCTGAAGC
ACTG-3′ (94◦C for 2 min, followed by 10 cycles of 94◦C
for 30 s, 58◦C for 30 s and 68◦C for 45 s, last strand elon-
gation at 65◦C for 5 min). We considered that a single cell
carries 6.81 × 10−12 g of genomic DNA. The 597 bp am-
plicons were then used for nested PCR with the following
primers: [7F2GFP NGS F2] 5′-AGGAAGGAAATGGG
CGGGGA-3′ and [7F2GFP NGS R2] 5′-AACTTCAGGG
TCAGCTTGCC-3′ (94◦C for 2 min, followed by 23 cycles
of 94◦C for 30 s, 62◦C for 30 s and 68◦C for 45 s, last strand
elongation at 65◦C for 5 min). The 429 bp PCR amplicons
were purified by PCR purification kit (Qiagen) and eluted
with 60 l of EB buffer (10 mM Tris–Cl, pH 8.5).
Library preparation and sequencing
Illumina sequencer compatible libraries were prepared
using a Kapa Hyper Prep Kit (Roche Sequencing and
Life Science) according to the manufacturers’ protocol.
Briefly, 40 ng of each PCR product was end repaired
and 3′-adenylated, and then ligated to NexTflex adaptors
(PerkinElmer, Inc., Bioo Scientific). The constructed li-
braries were subjected to 0.8× AMPure XP bead clean-
up and additional 0.7× AMPure XP bead clean-up (Beck-
man Coulter). The library quality was validated on a 2200
TapeStation from Agilent Technologies (Agilent, Santa
Clara, CA) and the library concentrations were determined
using a Kapa Library Quantification Kit (KAPA Biosys-
tems). The libraries were pooled and loaded on MiSeq (Il-
lumina) at a final concentration of 10 pM with 35% of PhiX
spike-in and subjected to 300 bp paired-end sequencing.
Bioinformatics for MiSeq data
For the sequence base quality control, we used FastQC and
the program named PEAR to concatenate MiSeq reads. Af-
ter that, we used the BWA-MEM program to align reads
and generate an SAM alignment file, which was used as
an input for the BAM-READCOUNT program to gener-
ate the genotype distribution and read coverage statistics
for each base position along the target genomic region. For
the structural variation analysis part, a customized analy-
sis program was developed using the SAM alignment file
to classify the reads into four classes, such as aligned reads
with only deletion events, aligned reads with only insertion
events, aligned reads with deletion and insertion events, and
soft-clipped reads that likely contain insertions or deletions
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based on the alignment CIGAR value for each aligned read,
we computed coordinates for each structural variation. For
example, a read with two deletions and two insertions will
generate four records; each record contains the coordinates
for the positions of the deletions or insertions as well as the
genotype sequence. For the soft-clipped read class, we first
realigned using the pairwise alignment function defined in
the Biostrings R package to detect large insertions and dele-
tions. Based on the detected structural variations, we con-
structed CIGAR values to generate the SAM file for the
IGC visualization. Then, we applied the same strategy to
generate the coordinates for each mutation, such as dele-
tions and insertions. After obtaining mutation coordinates
for each read, we applied different methods for deletion and
insertion events. For each deletion event, which was iden-
tified by the deletion start and end positions, we grouped
the reads that contained equal deletion start and end coor-
dinates, and computed the number of reads in this group
as the supporting evidence for such deletion events for this
deletion range. For insertions, since the coordinates for each
insertion are just one point, we classified the insertion se-
quence not only by the coordinates, but also by the length
of insertion sequence. For deletions, we found the MH se-
quence flanking the two sides for each deletion range. For
insertions, depending on the length of insertion sequence,
such as for short ones of 10 bp, we searched the flank-
ing regions and classified such an insertion sequence into
three classes as template, snapback and undetermined. For
longer insertion sequences, we searched for identification of
the hits in the EJ5 sequence and the whole human genome
sequence hg19, respectively. Reference sequences for high-
throughput sequencing analysis are listed in Supplementary
Table S1.
RESULTS
SBS3, ID6 and ID8 are enriched in BRCA-mutated cancers
expressing high levels of wild-type POLQ
Since POLQ performs mutagenic end joining, the detection
of POLQ-dependent unique mutation signatures may pro-
vide a means to monitor POLQ activity. It has been pro-
posed that the COSMIC3 mutation signature may reflect
POLQ mutagenesis (20,21). However, it has not yet been
demonstrated whether POLQ status is associated with the
enrichment of COSMIC3 in tumors.
We analyzed enrichment of any of the 82 COSMIC sig-
natures (65 SBS signatures or 17 ID signatures) accord-
ing to POLQ mRNA expression level and POLQ muta-
tion status in BRCA-mutated cancers (Supplementary Fig-
ure S1). POLQ expression was analyzed using RNA-seq
data; the top and bottom 33% were considered as POLQ
high-expression group and low-expression group, respec-
tively. Most signatures were not associated with POLQ sta-
tus. However, the proportion of SBS3 [a recently updated
version 3 signature related to COSMIC3, a version 2 signa-
ture (17)] was enriched to 54% in the wild-type POLQ high-
expression group in BRCA-mutated cancers (Figure 2A).
The proportions of ID6 and ID8 were enriched by 32% and
31%, respectively (Figure 2B). SBS3 is one of the single base
substitution signatures and is enriched in BRCA-mutated
cancers (18). ID6 and ID8 are insertion/deletion signatures
characterized by ≥5 bp deletions overlapping commonly
with ≥2 and ≤3 bp MH, respectively (18). SBS3, ID6 and
ID8 are signatures of MH-mediated end joining.
We further analyzed the relationship among those three
mutational signatures and POLQ and BRCA status. SBS3,
ID6 and ID8 were enriched more in BRCA1/2-mutated
cancers expressing high levels of wild-type POLQ than
in other conditions (Supplementary Figure S2A–C). ID6
strongly correlates with SBS3, but ID8 does not (18). We
confirmed the correlation of SBS3 and ID6 by the Pearson
correlation coefficient (R = 0.66, P < 2.2 × 10−16). The cor-
relations of SBS3 and ID8 (R = 0.36, P < 2.2 × 10−16) and
ID6 and ID8 (R = 0.31, P < 2.2 × 10−16) were weak (Sup-
plementary Figure S2D). SBS3, ID6 and ID8 signatures
were significantly enriched more than other types of mu-
tation signatures in BRCA1/2-mutated cancers expressing
wild-type POLQ (Supplementary Figure S2E). Other muta-
tional signatures including SBS40, SBS5, ID9, ID1 and ID2
were not significantly enriched more in BRCA1/2-mutated
cancers expressing wild-type POLQ than in other types of
cancers (Supplementary Figure S3A and B).
Our data suggest that detection of the SBS3, ID6 and ID8
signatures may be useful for monitoring POLQ activity in
tumors. However, these mutational signatures do not per-
fectly reflect POLQ mutagenesis. For example, ID6 includes
deletions that overlap with any length of MH, while POLQ
generally utilizes 2–6 bp MH for end joining (11,34). To im-
prove the pipeline to monitor POLQ-dependent mutation
signatures, it is important to enhance our understanding of
features of POLQ mutagenesis.
POLQ is involved in distal end joining
To directly explore the mechanism of POLQ action and mu-
tagenesis, we analyzed two configurations of end joining,
‘proximal’ (where a DSB is directly joined) and ‘distal’ (join-
ing of a break to a more distant break). A biological ex-
ample of distal EJ is CSR of immunoglobulin heavy chain
(IgH) genes. CSR is a ligation between two separated DSBs
(distal EJ), following targeted introduction of DSBs into
repetitive switch-region DNA elements in the IgH locus. In
the mouse, POLQ sometimes introduces insertions during
CSR (27). In the present experiments, the human POLQ
gene was disrupted in DR-U2OS and EDS-7F2 cell lines by
targeting the first exon with CRISPR/Cas9 (Supplementary
Figure S4A). The DR-U2OS cell line carries a DR-GFP re-
porter system to monitor homologous recombination (HR)
(29). The EDS-7F2 cell line carries pEJ5-GFP and pDsRed-
I-SceI reporter cassettes to monitor distal EJ and chromo-
some translocation (30). The CRISPR/Cas9 disruptions in-
troduced frameshift mutations in the open reading frame of
POLQ (Supplementary Figure S4B). Immunoblotting with
POLQ-specific antibody 1B1 (31) confirmed the absence of
POLQ in the established POLQ knockout cell lines (Supple-
mentary Figure S4C). The first exon sequences of POLQ in
the wild-type allele and targeted alleles are shown in Sup-
plementary Figure S4D.
To test the function of POLQ in distal EJ in human cells,
we utilized the EDS-7F2 cell line. In EDS-7F2 cells, three
specific I-SceI breaks can be induced by infection with a
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Figure 2. Mutation signatures enriched in BRCA-mutated tumors expressing wild-type or mutant form of POLQ. Proportions of 65 SBS (A) or 17 ID
(B) signatures are determined according to POLQ mRNA expression level (high: top 33rd percentile; low: bottom 33rd percentile) and POLQ mutation
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and chromosome translocations can be analyzed (30) (Fig-
ure 3A and B). The frequency of distal EJ (GFP+ cells) was
significantly reduced in two POLQ-deficient clones (EDS-
7F2 F7 and F10; Figure 3C). By contrast, the frequency of
chromosome translocation (DsRed+ cells) was significantly
increased in POLQ-deficient cells in this assay system (Fig-
ure 3D). The result is consistent with the reported function
of mouse POLQ in suppressing the Myc-IgH translocation
during CSR (27).
We found no statistically significant effect on HR by
POLQ deletion in three distinct POLQ-deficient clones
(Figure 3E and F) when we deleted the gene using
CRISPR/Cas9 in a U2OS cell line with the DR-GFP as-
say system stably integrated in the genome to determine the
POLQ knockout effect in human cells. Previous studies sug-
gested that knocking down of human POLQ inhibits HR
due to its interaction with RAD51 recombinase and inhi-
bition of RAD51 loading onto DNA (7,8). However, like
the human cells studied here Polq-deficient mice have nor-
mal levels of HR (35). A DR-GFP assay was used in all
those experiments to measure gene conversion initiated by
I-SceI-generated DSB (33).
POLQ-dependent mutation signature is enriched in proximal
end joining in NHEJ compromised cells
A better understanding of POLQ-dependent mutagenesis
will improve the analysis of POLQ activity in tumors us-
ing genome sequencing data. In this context, we asked what
genetic backgrounds influence POLQ mutagenesis in the
process of joining DSBs that are introduced at one spe-
cific site (proximal EJ) in cultured human cells. We em-
ployed CRISPR/Cas9 to generate a specific DSB at exon
6 of the HPRT gene in the POLQ-defective and -proficient
cells with stable knockdown of DNA-PKcs or 53BP1 us-
ing shRNA (Supplementary Figure S5A). Knockdown of
53BP1 in POLQ-defective cells is acutely toxic (20,21), but
some clones survived and could be recovered and used in
our analysis. End-joining products were isolated from the
cells after introducing a specific DSB at the targeted lo-
cus by the CRISPR/Cas9 vector carrying OFP as a co-
expression marker. We isolated OFP-positive cells as tar-
geted cells by FACS. Genomic DNA from OFP-positive
cells was isolated and the junction sequences were amplified
by PCR, sequenced and analyzed (Figure 4A). The effects
were determined by comparing the results from three inde-
pendent experiments. Cutoff numbers of sequencing reads
were determined based on Poisson distribution to exclude
noise reads that occurred due to PCR and sequencing er-
rors. The sequences found at less than the cutoff number
(the Poisson 90%, 95% or 99% confidence interval depend-
ing on sample) were considered as background noise (Sup-
plementary Table S2).
In our assay system, ∼90% of targeted loci were joined
precisely (Figure 4B). We identified sequences that show
‘deletion with overlapping 3–6 bp of MH at the end-joining
site’ as POLQ-mediated events. In human cells, end-joining
junctions formed by NHEJ and TMEJ contain commonly
0–2 and 2–6 bp of MH, respectively (11,34). Those data
match with biochemical activity of POLQ. POLQ requires
a minimum of 2 bp and optimally 4 bp between a template
and primer pair for efficient and processive DNA synthe-
sis in vitro (36,37). We analyzed ∼10% of targeted loci that
were imprecise end-joining products and found that unlike
mouse cells (20), the frequency of this class of mutations was
not influenced by disruption of POLQ alone in human cells.
However, this signature increased significantly with DNA-
PKcs or 53BP1 depletion. This increase was significantly
reduced by POLQ deletion, indicating the mutation signa-
ture is due to POLQ activity (Figure 4C and Supplementary
Table S3).
We also found that POLQ single deletion did not influ-
ence the frequency of imprecise end joining in human cells
in the DR-GFP assay system in the absence of defects in ad-
ditional DSB repair genes (Supplementary Figure S5B and
C) when analyzed with a different method. Genomic DNA
was isolated from pooled DR-U2OS cells following expres-
sion of I-SceI. In this assay system, if the I-SceI DSB is re-
paired by HR, the site becomes BcgI sensitive; if repaired
by precise NHEJ, the site is still I-SceI sensitive; and if re-
paired by imprecise end joining (e.g. TMEJ), the sequence
becomes resistant to I-SceI and BcgI (33).
Insertions were also identified at the junction sites. How-
ever, the majority of such events were insertion of a single
T:A base pair. This is most likely a correct nucleotide in-
sertion at the 1 bp staggered end, a preferred substrate of
NHEJ (38). It has been reported that Cas9-catalyzed DNA
cleavage produces 1 bp staggered ends rather than blunt
ends (39). The 1 nt staggered ends generated by Cas9 are
likely filled and joined by NHEJ. This activity was not in-
fluenced by POLQ, 53BP1 or DNA-PKcs. Although 53BP1
and DNA-PKcs influence NHEJ efficiency, those activities
are not essential for end filling or end joining for the 1 nt
staggered ends. 53BP1 inhibits resection of DNA breaks
(40) and DNA-PKcs activates Artemis endonuclease activ-
ity (41) (Supplementary Figure S6AB and Supplementary
Table S4).
POLQ-dependent mutation signatures including MH-
mediated templated insertions are enriched in distal end
joining
POLQ-mediated nucleotide insertion was a rare event in our
proximal end-joining assay system. We hypothesized that
such events might be more common during distal EJ. POLQ
introduces sequence insertions at end-joining sites during
the distal end-joining process of CSR (27). Interestingly, in-
duction of CSR by treatment of mouse B cells with IL-4 and
lipopolysaccharide leads to upregulation of Polq in those
cells, but not other genes including Poln, Helq, Pold1 and
Haus3 (42). This is consistent with a role for POLQ in dis-
tal EJ.
We set out to test whether POLQ-dependent mutation
signatures including templated insertions can be detected
in nuclease-induced distal EJ. We isolated genomic DNA
from GFP-positive POLQ+/+ or POLQ−/− EDS-7F2 cells,
in which two distal I-SceI breaks were joined (Figure 3C).
PCR amplicons for the junction region were analyzed by
high-throughput sequencing (Figure 5A). Cutoff numbers
(the Poisson 99% confidence interval) were used to exclude
noise reads that occurred due to the PCR and sequencing
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Figure 3. POLQ is involved in distal EJ. (A) Detection of distal EJ and chromosome translocation in human cells. The human bladder carcinoma cell line
EDS-7F2 harbors a pEJ5-GFP construct on one chromosome and a pDsRed-I-SceI construct on another chromosome. For the break end-joining assay,
the GFP gene and the DsRed genes are initially inactive due to the lack of a promoter but become activated following NHEJ between the I-SceI-induced
DSBs. (B) Following infection with a retrovirus expressing I-SceI, the percentage of cells expressing GFP (distal EJ) or DsRed (chromosome translocation)
was determined by flow cytometry. The frequencies of GFP+ (C) and DsRed+ (D) cells were determined in EDS-7F2 (7F2) and two POLQ knockout EDS-
7F2 clones (F7 and F10). Error bars represent standard deviation of three separate experiments. The differences between 7F2 and POLQ−/− cells (F7, F10)
are statistically significant (P ≤ 0.05, unpaired t-tests). (E) POLQ knockout U2OS cell lines carry the recombination reporter DR-GFP integrated into
the genome. SceGFP is a GFP gene that contains an I-SceI endonuclease site within the coding region. Cleavage of the I-SceI site in vivo and repair by HR
directed by the downstream iGFP results in GFP+ cells. (F) HR in POLQ+/+ cells (DR-U2OS) and POLQ−/− cells (F5, F10, G6) after I-SceI expression.
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Figure 4. POLQ mutation signature accumulates in the absence of NHEJ in proximal EJ. (A) HPRT locus was targeted by CRISPR/Cas9. The cells
expressing OFP, a co-expression marker, were isolated and the products of proximal EJ were characterized by target site amplification and high-throughput
sequencing (NGS). The percentage of all proximal end-joining products with no mutation (B) and a POLQ mutation signature (deletion overlapping with
3–6 bp MH at the proximal end-joining site) (C). Unpaired t-tests were performed for statistic comparison. Parental DR-U2OS and POLQ−/− clones (F10
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Figure 5. POLQ performs MH-mediated end joining and insertion in distal EJ. (A) Distal end-joining products isolated from GFP-positive cells were
characterized by target site amplification and high-throughput sequencing (NGS). The percentage of end-joining products with no mutation (B) and
different length MH (C). The percentage of different length of insertion (D), different types of insertion (E), insertions initiated with MH (F), insertions
ended with MH (G) and insertions initiated and ended with MH (H). Unpaired t-tests were performed for statistical analysis (ns denotes P > 0.05; *P ≤
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bp deletion, detected when the two I-SceI break sites were
simply joined, as end joining with no mutation. Mutations
at the end-joining sites were identified in >50% of the se-
quences. Overall, a higher fraction of mutated sequences
was found in POLQ−/− cells (Figure 5B). In the deleted end-
joining products, we found products overlapping with up to
4 bp of MH. The frequency of 4 bp MH was significantly re-
duced but the proportion of joining events with <4 bp MH
was increased in POLQ−/− clones. Products generated by
Ku-mediated NHEJ [enriched for end joining with <4 bp
MH (38,43)] likely increased in the absence of POLQ in this
assay system. POLQ, which utilizes MH ranging between 2
and 6 bp (11,34), mediates the end joining with 4 bp MH
(Figure 5C and Supplementary Table S6).
We next analyzed insertions generated at the end-joining
sites. More insertions were identified in POLQ-proficient
cells than POLQ-deficient cells. Insertions of ≥5 bp (up
to 15 bp) occurred at significantly lower frequency in
POLQ knockout cells (Figure 5D and Supplementary Table
S7). We analyzed 5–15 bp insertions and categorized into
five groups: distant, nearby, snapback, direct repeat and
random. The ‘distant’ and ‘nearby’ categories are in trans
insertions copied from template encoded >100 and <100
bp downstream or upstream from the end-joining junctions,
respectively. The ‘snapback’ category refers to cis inser-
tions copied from sequence existing upstream on the same
strand. The ‘direct-repeat’ sequences are direct duplications
of flanking DNA. Sequence insertions without an obvious
template are ‘random’. We considered distant, nearby, snap-
back and direct-repeat insertions as templated insertions,
and these were significantly reduced in POLQ−/− cells (Fig-
ure 5E). We analyzed MH usage in distant, nearby and
snapback insertions and found that those templated inser-
tions were often initiated using MH by POLQ (Figure 5F)
and that sequences at the end of the insertions are often
used for MH-mediated end joining by POLQ (Figure 5G).
Furthermore, templated insertions initiated and completed
with MH were also significantly reduced in POLQ−/− cells
(Figure 5H and Supplementary Table S8). The origin of
DNA synthesis was inferred based on the position of the
templated sequence. For example, when the templated se-
quence was found downstream of the second I-SceI site
(3530–3547), we considered the first I-SceI site (1758–1775)
as the origin for the distant templated insertion. We consid-
ered that the second I-SceI site was the origin for the snap-
back templated insertion (Supplementary Tables S1 and
S8).
POLQ utilizes MH to initiate copying of sequences and
also to join broken ends (Figure 6A). Templated insertions
(5–15 bp) were often generated at the border of the I-SceI
cleavage site (258:257) and at slightly further back from
the break site (253:252; Figure 6B). By contrast, insertions
at the original I-SceI break site 262:261 were found only
rarely. One possible reason is that distal EJ occurs when
individual breaks fail to undergo direct end joining. Such
substrates, which were not repaired by NHEJ or HR, may
be predominantly repaired by TMEJ. The position of MH-
mediated insertions was not random, but instead specifi-
cally utilized embedded MH sequences. Templated inser-
tions were copied from various regions of the inserted EJ5
construct DNA and their sequence locations are shown in
Figure 6C.
DISCUSSION
SBS3, ID6 and ID8 reflect POLQ mutagenesis
In this study, we have demonstrated that specific COS-
MIC signatures, SBS3 and ID6 and ID8, are enriched in
BRCA-mutated cancers that express high levels of wild-type
POLQ. Those signatures may therefore be useful indicators
of POLQ activity.
SBS3 is a single base substitution signature at all bases
except C to D (D = A/G/T) substitutions at 5′-CG se-
quences, indicating that the signature is not associated with
deamination of 5-methylcytosine (5-meC). 5-meC occurs
predominantly at 5′-CG sequences in gene promoters. It is
generally associated with transcriptional silencing. 5-meC
residues in ssDNA are deaminated three times faster than
C residues (44). Deamination of 5-meC results in the forma-
tion of thymine and hence of TG mispairs (45). Since C to T
transitions at 5′-CG sequences are rare, SBS3 may be asso-
ciated with DSBs at actively transcribing promoter regions
that are not methylated. Indeed, Topoisomerase II induces
DSBs within promoter regions to facilitate the expression
of a subset of genes (46). POLQ may process those DSBs
especially in BRCA-mutated cancers. Interestingly, the ma-
jority of SBSs (68%) made by POLQ in vitro were generated
when copying a template A or T. 5′-CG sequences were not
POLQ hot spots (15). There is a resemblance between SBS3
and the POLQ base substitution signature.
ID6 is the most enriched signature among the ID signa-
tures. It is a signature of MH-mediated end joining charac-
terized by ≥5 bp deletions, commonly overlapping with ≥2
bp MH at breakpoint junctions. POLQ utilizes 2–6 bp MH
for end joining (11,34); thus, ID6 closely reflects POLQ mu-
tagenesis. ID8 is the second most enriched signature. ID8
encompasses deletions with short MH (commonly ≤3 bp),
which are likely end-joining products by NHEJ. Although
it is not an ideal substrate, POLQ can extend DNA from a
primer annealed with 2 bp MH (36,37). ID8 thus appears to
be the mixture of signatures generated by NHEJ and TMEJ.
Other mutational signatures including SBS40, SBS5,
ID9, ID1 and ID2 were also enriched in BRCA1/2-mutated
cancers expressing high levels of wild-type POLQ. How-
ever, they were not significantly enriched more in BRCA1/2-
mutated cancers expressing wild-type POLQ than in other
types of cancers (Supplementary Figure S3). SBS40 and
SBS5 are correlated with age of cancer diagnosis and con-
tribute to multiple types of cancer (18). The association be-
tween those signatures and POLQ activity is unknown. ID9,
ID1 and ID2 are signatures of single base insertion and
deletion at homopolymeric runs (18). This matches with the
biochemical observation that POLQ adds and deletes sin-
gle nucleotides during DNA replication of long mononu-
cleotide tracts at particularly high rates (15). POLQ activity
might therefore contribute to ID9, ID1 and ID2.
POLQ has a role in mediating distal end joining in DSB re-
pair
The major function for POLQ is in the defense against
DSBs. It has been proposed that POLQ functions in sup-
pressing HR by modulating RAD51 loading (7,8). How-
ever, this is unlikely because RAD51 is orders of magni-
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Figure 6. POLQ performs MH-mediated templated insertions. (A) A model of MH-mediated templated insertion. POLQ binds to the end of 3′ DNA tail
following DNA resection and extends DNA using MH. Sometimes the sequence of the 3′ end of the extended DNA is used for MH-mediated end joining.
Red: MH used to initiate DNA extension; black: copied sequence for insertion; green: 3′ end of the insertion that is sometimes used for MH-mediated end
joining. (B) Hot spots for templated insertion (distant, nearby and snapback) initiated with or without MH. The number indicates the sequence position
of the 429 bp PCR products for the intact allele (Supplementary Table S1). End-joined I-SceI sequence is 253:252–270:271. I-SceI cut site is 262:261.
Percentage of each insertion is shown and the scores >0.1% are displayed in bold. (C) Positions of copied sequence for templated insertions (distant,
nearby and snapback) are shown with percentage. Sequence with more than two possible copied sequences was excluded (Supplementary Figure S8). The
number indicates the sequence position of the 9406 bp EJ5 reporter construct (Supplementary Table S1). The positions of the two I-SceI sites are 1758–1775









atl Inst of Science & Technology user on 06 January 2021
NAR Cancer, 2020, Vol. 2, No. 3 13
POLQ-defective cells may be a sign of aborted recombina-
tion events. Some breaks (e.g. those with resection) are best
repaired by TMEJ, and if TMEJ is absent, HR cannot suc-
cessfully process them. In a DR-GFP assay in U2OS cells,
HR was reported to increase ∼2-fold after siRNA-mediated
POLQ knockdown (7,8). However, HR efficiency measured
by the DR-GFP assay in mouse cells was not affected after
knocking out Polq (35). In this study, we knocked out the
POLQ gene in the U2OS DR-GFP (DR-U2OS) cells and
also found that HR was not affected by POLQ single dele-
tion in human cells.
Our data reveal a role for POLQ in distal EJ. Distal
EJ is reduced in the absence of POLQ (Figure 3) and
POLQ-dependent mutation signatures are enriched in dis-
tal EJ (Figure 5). On the other hand, the POLQ-dependent
mutation signature in proximal EJ increases only when the
NHEJ pathway is perturbed (Figure 4). The results indicate
that proximal EJ is predominantly processed by NHEJ, but
distal EJ is often processed by TMEJ. This may explain en-
richment of POLQ-dependent templated insertions during
CSR, a physiological example of distal EJ (27). Transloca-
tions joining parts of different chromosomes are also exam-
ples of distal EJ, and are another candidate for future anal-
ysis for the presence of a TMEJ signature at translocation
sites.
POLQ uses resected DNA ends as substrates, but those
resected ends may be modified to allow for repair by NHEJ
in the absence of POLQ. For example, CTC1–STN1–TEN1
(CST)–Pol fills in such resected DNA ends to promote
NHEJ (47). NHEJ usually performs end joining with <4
bp MH (38), which could account for the increase in dis-
tal end-joining products with <4 bp MH in the absence of
POLQ (Figure 5C).
TMEJ is an important alternative for other DSB repair
pathways, NHEJ and HR (Figure 1). TMEJ is protective for
genome stability, in the sense that an absence of POLQ leads
to large deletions in some conditions, such as an NHEJ-
deficient background (11,19). Our data reveal a role for
POLQ in preventing chromosome translocations. The use
of TMEJ results in an increase in short deletions and inser-
tions, but it helps prevent catastrophic large deletions and
chromosome rearrangements.
In summary, we have identified here several POLQ-
associated mutation signatures. These are COSMIC signa-
tures SBS3 and ID6, deletions with 3–6 bp MH arising from
proximal EJ in the absence of NHEJ and templated inser-
tions arising from distal EJ. Currently, genomic sequencing
of tumor biopsies is increasingly done with the intention of
informing treatment decisions. Tumors enriched for these
POLQ-associated signatures may have lost functional HR
or NHEJ, and subsequently may be hypersensitive to POLQ
inhibition and DSB-inducing therapies. The better under-
standing of POLQ-induced mutation signatures as reported
here will help to develop more effective pipelines to detect
POLQ-dependent mutation signatures in genome sequenc-
ing data.
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